Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYN NYSE:GRDN NASDAQ:IMCR NASDAQ:SNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$13.20-0.4%$10.96$6.36▼$37.08$1.93B1.12.61 million shs3,224 shsGRDNGuardian Pharmacy Services$28.75-0.4%$22.89$14.16▼$28.98$1.82BN/A332,943 shs225,465 shsIMCRImmunocore$36.43-0.6%$33.80$23.15▼$39.33$1.85B0.77295,200 shs213,173 shsSNDAShanda Interactive Entertainment$25.76+12.9%$0.00$19.34▼$32.90$479.80M1.8352,862 shs32,857 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics-0.38%-1.85%+18.73%-9.06%-59.19%GRDNGuardian Pharmacy Services-0.10%+7.56%+44.03%+42.29%+2,868,999,900.00%IMCRImmunocore-0.14%+13.42%+14.45%+2.90%+8.03%SNDAShanda Interactive Entertainment-0.39%+1.04%+6.31%+2.36%-0.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$13.20-0.4%$10.96$6.36▼$37.08$1.93B1.12.61 million shs3,224 shsGRDNGuardian Pharmacy Services$28.75-0.4%$22.89$14.16▼$28.98$1.82BN/A332,943 shs225,465 shsIMCRImmunocore$36.43-0.6%$33.80$23.15▼$39.33$1.85B0.77295,200 shs213,173 shsSNDAShanda Interactive Entertainment$25.76+12.9%$0.00$19.34▼$32.90$479.80M1.8352,862 shs32,857 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics-0.38%-1.85%+18.73%-9.06%-59.19%GRDNGuardian Pharmacy Services-0.10%+7.56%+44.03%+42.29%+2,868,999,900.00%IMCRImmunocore-0.14%+13.42%+14.45%+2.90%+8.03%SNDAShanda Interactive Entertainment-0.39%+1.04%+6.31%+2.36%-0.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 3.06Buy$34.07158.08% UpsideGRDNGuardian Pharmacy Services 3.00Buy$25.67-10.71% DownsideIMCRImmunocore 2.45Hold$56.8956.16% UpsideSNDAShanda Interactive Entertainment 2.00Hold$26.000.95% UpsideCurrent Analyst Ratings BreakdownLatest SNDA, DYN, IMCR, and GRDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025IMCRImmunocoreZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/25/2025IMCRImmunocoreJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$34.00 ➝ $13.007/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.007/29/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.00 ➝ $31.007/29/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $38.007/15/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$10.00 ➝ $9.007/11/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/26/2025DYNDyne TherapeuticsJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AGRDNGuardian Pharmacy Services$1.33B1.37$0.25 per share115.66$2.37 per share12.13IMCRImmunocore$310.20M5.92N/AN/A$7.20 per share5.06SNDAShanda Interactive Entertainment$255.32M1.92N/AN/A($14.07) per share-1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)GRDNGuardian Pharmacy Services-$87.29M-$1.52N/A34.22N/A-6.90%-52.41%-24.17%11/11/2025 (Estimated)IMCRImmunocore-$51.09M-$0.40N/AN/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)SNDAShanda Interactive Entertainment-$21.11M-$1.85N/AN/AN/A-4.02%N/A-6.11%N/ALatest SNDA, DYN, IMCR, and GRDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/AGRDNGuardian Pharmacy ServicesN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ASNDAShanda Interactive EntertainmentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne Therapeutics0.1716.8316.83GRDNGuardian Pharmacy ServicesN/A1.180.88IMCRImmunocore1.015.895.86SNDAShanda Interactive Entertainment6.972.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%GRDNGuardian Pharmacy ServicesN/AIMCRImmunocore84.50%SNDAShanda Interactive Entertainment87.55%Insider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics20.77%GRDNGuardian Pharmacy Services63.71%IMCRImmunocore10.40%SNDAShanda Interactive Entertainment5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100142.26 million112.72 millionOptionableGRDNGuardian Pharmacy Services3,40063.32 million22.98 millionN/AIMCRImmunocore32050.39 million45.15 millionOptionableSNDAShanda Interactive Entertainment3,95519.07 million18.12 millionNot OptionableSNDA, DYN, IMCR, and GRDN HeadlinesRecent News About These CompaniesSonida Closes Previously Announced Senior Living Asset Acquisition in Dallas-Fort Worth2 hours ago | businesswire.comSonida Senior Living (SNDA) Reports Q2 Loss, Beats Revenue EstimatesAugust 11, 2025 | zacks.comSonida Senior Living, Inc. (SNDA) Q2 2025 Earnings Conference Call TranscriptAugust 11, 2025 | seekingalpha.comSonida Senior Living Celebrates Growth and Community in Greater Atlanta RegionJuly 30, 2025 | businesswire.comVista Building at The Wellington at North Bend Crossing Secures Ohio Licensure, Opening Doors for New Assisted Living and Memory Care ResidentsJuly 30, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comSonida Senior Living Announces First Quarter 2025 ResultsMay 12, 2025 | businesswire.comSonida Announces Participation in Upcoming ConferencesMay 8, 2025 | businesswire.comThe Wellington at North Bend Crossing Expands Assisted Living and Memory Care Services, Coming Summer 2025May 2, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q4 2024 Earnings Call TranscriptMarch 17, 2025 | seekingalpha.comSonida Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference CallMarch 3, 2025 | businesswire.comSonida to Participate in Citi's 30th Annual Global Property CEO ConferenceFebruary 17, 2025 | businesswire.comSonida Senior Living Advances Clinical Excellence with August HealthFebruary 6, 2025 | businesswire.comSonida Announces Latest Asset Acquisition and Closing of Fannie Mae Maturity ModificationsJanuary 6, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comSonida Senior Living Announces Third Quarter 2024 ResultsNovember 13, 2024 | businesswire.comSonida Continues Executing on its Accretive Growth and Capital Allocation Strategy with $48 Million of InvestmentsNovember 5, 2024 | businesswire.comSunda Energy Share Chat (SNDA)November 4, 2024 | lse.co.ukInteractive Harry Potter art experience to open on Sentosa on Nov 22November 1, 2024 | straitstimes.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDA, DYN, IMCR, and GRDN Company DescriptionsDyne Therapeutics NASDAQ:DYN$13.20 -0.05 (-0.38%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Guardian Pharmacy Services NYSE:GRDN$28.74 -0.11 (-0.36%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.Immunocore NASDAQ:IMCR$36.43 -0.21 (-0.57%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Shanda Interactive Entertainment NASDAQ:SNDAShanda Interactive Entertainment Limited (Shanda Interactive) is an interactive entertainment media company. The Company offers a range of entertainment content portfolio, including among other things, massively multiplayer online role-playing game (MMORPG), advanced casual games and browser-based games without user-end software through Shanda Games, online (Internet and wireless value added services (WVAS)) and offline literature publication through Cloudary Corporation, a social network game community, including among others, online chess and board games, e-sports game platform and table game platform through Shanda Casual Community, WVAS and music through Hurray and online video through Ku6. In February 2012, Shanda Interactive merged with Premium Lead Company Limited and New Era Investment Holding Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
